iwNHL 2022

09–11 September 2022 | Barcelona, Spain

VJHemOnc is pleased to be the official media partner for the 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL), which was held in Barcelona, Spain, on 9 – 11 September, 2022.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in non-Hodgkin lymphoma with the aim to optimize clinical care.

T-cell lymphoma Immunotherapy Managing FL beyond first-line therapy T-cell therapies Novel therapies BTK inhibitors BiTEs versus CARs

Session 1: T-cell lymphoma

Laurence de Leval

Updates in pathology & classification of gastrointestinal T-cell neoplasms

Laurence de Leval Lausanne University Hospital, Lausanne, Switzerland

Genetics and epigenetics of T-PLL

Reiner Siebert Ulm University, Ulm, Germany

AUTO4 CAR-T in T-cell lymphoma

Kate Cwynarski University College Hospital, London, United Kingdom

What is new in the treatment of cutaneous T-cell lymphomas

Steven Horwitz Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 2: Immunotherapy of lymphoma

Engaging the innate & adaptive antitumor immune response in lymphoma

Stephen Ansell Mayo Clinic, Rochester, MN, United States

video coming soon

CAR-T and the tumor microenvironment - DLBCL as a model

John Kuruvilla Princess Margaret Cancer Centre, Toronto, Canada

video coming soon

Francisco Hernandez-Ilizaliturri

IMiDs in combination

Francisco Hernandez-Ilizaliturri Roswell Park Cancer Institute, Buffalo, NY, United States

video coming soon

Checkpoint inhibitors

Gaël Roué Josep Carreras Leukemia Research Institute, Barcelona, Spain

video coming soon

Salvage and bridging treatments in R/R LBCL

Georg Lenz Münster University Hospital, Münster, Germany

Kieron Dunleavy

Double-hit lymphoma - optimizing therapy

Kieron Dunleavy George Washington University, DC, WA, United States

video coming soon

Session 4: Management of follicular lymphoma beyond first-line therapy

Epigenetic alterations in the development of FL

Jessica Okosun Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Transformed FL treatment options

Anna Sureda Catalan Institute of Oncology, Barcelona, Spain

Mechanisms of action and opportunities for synergy in FL-directed therapies

David Qualls Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 5: T-cell therapies for lymphoma

Jeremy Abramson

CD19-CAR-T – real-world experience (commercial CARs)

Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States

CD19-CAR-T – next-generation CD19-CAR-T (Humanized CARs, allo ‘off-the-shelf’ CARs etc)

David Maloney Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Maksim Mamonkin

CAR-T for T-cell lymphoid malignancies - using T-ALL as an example

Maksim Mamonkin Baylor College of Medicine, Houston, TX, United States

Catherine Bollard

Third party EBV T-cells for EBV lymphomas

Catherine Bollard Children's National Research Institute, Washington D.C., WA, United States

Session 6: Novel therapies part 1 – ADCs

POLARIX – Polatuzumab vedotin

Laurie Sehn BC Cancer Agency, Prince George, Canada

Carmelo Carlo-Stella

Loncastuximab tesirine

Carmelo Carlo-Stella Humanitas University, Milan, Italy

ADCT-301 – Camidanlumab tesirine

Graham Collins Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Brentuximab vedotin

David Straus Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Session 6: Novel therapies part 2 – CD20/CD3 bispecific antibodies

Redirecting T-cell activity with anti-BCMA/anti-CD3 bispecific antibodies in CLL

Arnon Kater University of Amsterdam, Amsterdam, Netherlands

Loretta Nastoupil

Mosunetuzumab

Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Carmelo Carlo-Stella

Glofitamab

Carmelo Carlo-Stella Humanitas University, Milan, Italy

Odronextamab (REGN1979)

Rajat Bannerji Rutgers Cancer institute of New Jersey, Newark, NJ, United States

Session 8: BTK inhibitors

Loretta Nastoupil

Ibrutinib combinations

Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Alessandra Tedeschi

Zanubrutinib

Alessandra Tedeschi Niguarda Cancer Center, Milan, Italy

Acalabrutinib

Marek Trněný Charles University Hospital, Prague, Czech Republic

Pirtobrutinib (LOXO-305)

Anthony Mato New York City, NY, United States

Session 9: Point/counterpoint – BiTEs versus CARs for NHL

Point: CAR-T for NHL

Jason Westin MD Anderson Cancer Center, Houston, TX, United States

Marion Subklewe

Counterpoint: BiTEs for NHL

Marion Subklewe LMU Hospital Munich, Munich, Germany

iwNHL 2022 was supported by: